The purpose of this study is to determine if the study drug, inhaled nitric oxide (iNO), when given and breathed through an investigational study device, the INOpulse, may help treat patients at risk for pulmonary hypertension-pulmonary fibrosis. Another purpose of this study is to determine if using the INOpulse delivery device (drug and device combination) improves the levels of moderate to vigorous physical activity (for example walking, climbing stairs, household chores and cleaning and, exercise and hobbies), as measured by actigraphy (a non-invasive way to monitor rest/activity).
The purpose of this study is to assess the safety and effectiveness of the GORE® EXCLUDER® Conformable AAA Endoprosthesis (Study Device) when used for the treatment of Abdominal Aortic Aneurysms (AAA).
This research will be conducted by the SIU Memory and Aging Network (MAN), which comprises 38 sites that evaluate and treat patients with dementia throughout non-metropolitan Illinois. AD patients and their caregivers who are living in private homes will be recruited. Primary outcome measures will be the ratings of the caregiver’s physical status (grip strength, walking speed, and score on the Timed Up-and-Go Test11 and the rating of the caregiver’s chronic medical illness burden using the Cumulative Illness Rating Scale (Geriatric).12,13 The patient and caregiver dyad is required.
The purpose of the study is to demonstrate the safety and effectiveness of the BioVentrix Revivent TC System for the treatment of LV antero-septal aneurysms/scars in patients with symptomatic heart failure.
I5T-MC-AACI: Alzheimer’s is a disease that attacks the brain, causing problems with memory, thinking, and behavior. Symptoms usually develop slowly and get worse over time, eventually making daily tasks impossible. Although we don’t know the exact cause, researchers found out that the two proteins called tau and amyloid are building up in brains of people with Alzheimer’s disease even before they have any symptoms.
Lauriet: The purpose of this study is to compare the effects, good or bad, of MTAU9937A versus placebo on patients with moderate AD. In this study, you will get either MTAU9937A or placebo. MTAU9937A is an experimental drug, which means health authorities such as the Food and Drug Administration (FDA) have not approved it for the treatment of moderate AD or other conditions. MTAU9937A is in early development and has been previously studied in healthy subjects and people with milder forms of Alzheimer’s disease.
The purpose of this clinical study is to see whether a medical device called the Paradise Renal Denervation System (also called The Paradise System) can lower high blood pressure in patients who are known to have hypertension.